[go: up one dir, main page]

WO2025165825A1 - Compositions orales topiques pour piéger des médicaments/toxines dans la salive et leurs procédés de fabrication et d'utilisation - Google Patents

Compositions orales topiques pour piéger des médicaments/toxines dans la salive et leurs procédés de fabrication et d'utilisation

Info

Publication number
WO2025165825A1
WO2025165825A1 PCT/US2025/013523 US2025013523W WO2025165825A1 WO 2025165825 A1 WO2025165825 A1 WO 2025165825A1 US 2025013523 W US2025013523 W US 2025013523W WO 2025165825 A1 WO2025165825 A1 WO 2025165825A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
buprenorphine
oral
saliva
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/013523
Other languages
English (en)
Inventor
Ming Hu
Rashim SINGH
Rongjin SUN
Vesna Tumbas SAPONJAC
Emanuel BALTRIP
Barbara Mae ABAD
Shujian HU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanarentero LLC
University of Houston System
Original Assignee
Sanarentero LLC
University of Houston System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanarentero LLC, University of Houston System filed Critical Sanarentero LLC
Publication of WO2025165825A1 publication Critical patent/WO2025165825A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof

Definitions

  • the present disclosure relates generally to the fields of medicine, opioids and oral biology. More particular, the disclosure relates to oral scavenging formulations to remove toxins or drugs from the oral cavity of a subject.
  • an oral composition comprising an absorbent and/or adsorbent.
  • the composition may comprise a gum, such as at up to 50% wt/wt of the composition.
  • the absorbent/adsorbent may be Fullers Earth, diatomaceous earth, bentonite zeolite, kaolin, charcoal, silica, diatomaceous earth, kaolin, starch, sodium aluminosilicate, or any synthetic, surface modified or coated absorbent/adsorbent.
  • the composition may further comprise one or more of a saliva stimulator, a flavoring agent, an anti-microbial, an anti-fungal, topical anesthetic, and antibiofilm material.
  • the composition may be in the form of an oral patch, a film, a wafer, a periodontal chip, or a chewable pellet.
  • Also provided is method of removing a substance from the oral cavity of a subject comprising delivering the composition as described herein for a set period of time and removing said composition after the end of said set period of time.
  • the period of time may be up to 60 mins or up to 15-20 mins, or up to 15, 16, 17, 18, 19 or 20 mins.
  • the substance may be a drug, metabolite, toxin or bioagent, such as an opioid.
  • the subject may be an opioid (ab)user, such as an opioid abuser undergoing medication-assisted treatment, such as wherein medication-assisted treatment is in the form of sublingual buprenorphine.
  • Absorbents are defined herein to agents that soak up materials into their structure, while adsorbents are defined herein as agents collect materials on their surface
  • FIGS. 1A-D Adsorption of 5-FU (FIG. 1A), SN-38 (FIG. IB) and buprenorphine (FIG. 1C), (FIG. ID) on adsorbents.
  • FIGS. 2A-C Chemical structures of 5-FU (FIG. 1A), SN-38 (FIG. IB) and buprenorphine (FIG. 1C).
  • FIG. 3 Langmuir isotherm model for adsorption of buprenorphine on bentonite.
  • FIG. 4 Buprenorphine scavenging capacity from saliva fluid by adsorbents/absorbents. Statistical analysis was performed with One-way ANOVA. * Means p ⁇ 0.05, ** means p ⁇ 0.01, *** means p ⁇ 0.001.
  • FIG. 5 Time and concentration-dependent reduction in saliva buprenorphine concentration by control (CTRL) vs DE chewing gum compositions.
  • CTRL saliva buprenorphine concentration by control
  • FIG. 6 Chewing gum Formulation 1.
  • FIG. 7 Chewing gum Formulation 2.
  • the inventors established a positive association between the occurrence of dental caries and sublingual buprenorphine and high accumulation of buprenorphine in salivary glands, resulting in high long-term exposure of oral tissue to the buprenorphine.
  • the inventors showed higher preferential accumulation of buprenorphine in rat salivary gland upon sublingual administration (>100 times higher concentration in salivary glands than in plasma) as compared to i.v.
  • Prolonged exposure of oral cavity to high concentrations of drug can result in the reduction of salivary production due to anticholinergic activity of opioids which further disturbs the microbiota balance in mouth, e.g., rising growth of Streptococci mutans, and altering of normal pH, which together significantly increase the risk of teeth erosion.
  • Topical oral compositions used in dentistry such as oral patches, wafers and films, periodontal chips, and chewing gums, have the capacity to deliver substances (antimicrobials, fluoride, etc.) for protection of oral health in a more convenient way than usual toothbrushing or mouth washing (rinsing).
  • substances antiimicrobials, fluoride, etc.
  • These compositions have been used as a vehicle for administration of drugs to oral tissue and systemic delivery. Examples include lidocaine and insulin release, canker sore buccal patches, nicotine chewing gum, periodontal chips with chlorhexidine gluconate (PerioChip), all of which are used.
  • compositions and methods of use for removing drugs or toxins, such as buprenorphine (and/or its metabolites), from oral cavity comprising the steps of providing at least one topical oral composition comprising adsorbing or absorbing complex, such as charcoal, silica, diatomaceous earth, kaolin, sodium aluminosilicate, providing scavenging of drug/toxin to said user by transferring of drug from saliva of said user to the topical oral composition by residing in oral cavity, said topical oral composition involving a transfer of drug/toxin from salivary gland to saliva of said user in a customary period during topical oral composition residence in oral cavity.
  • adsorbing or absorbing complex such as charcoal, silica, diatomaceous earth, kaolin, sodium aluminosilicate
  • Buprenorphine sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant.
  • opioid use disorder it is typically started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health-care provider.
  • buprenorphine/naloxone In the United States, the combination formulation of buprenorphine/naloxone (Suboxone) is usually prescribed to discourage misuse by injection. However, more recently the efficacy of naloxone in preventing misuse has been brought into question, and preparations of buprenorphine combined with naloxone could potentially be less safe than buprenorphine alone. Maximum pain relief is generally within an hour with effects up to 24 hours.
  • Buprenorphine affects different types of opioid receptors in different ways. Depending on the type of opioid receptor, it may be an agonist, partial agonist, or antagonist.
  • Buprenorphine's activity as an agonist/antagonist is important in the treatment of opioid use disorder: it relieves withdrawal symptoms from other opioids and induces some euphoria, but also blocks the ability for many other opioids, including heroin, to cause an effect. Unlike full agonists like heroin or methadone, buprenorphine has a ceiling effect, such that taking more medicine past a certain point will not increase the effects of the drug.
  • Side effects may include respiratory depression (decreased breathing), sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction.
  • respiratory depression decreased breathing
  • adrenal insufficiency a risk exists of further seizures.
  • Opioid withdrawal following stoppage of buprenorphine is generally less severe than with other opioids. Whether use during pregnancy is safe is unclear, but use while breastfeeding is probably safe, since the dose the infant receives is 1 -2% that of the maternal dose, on a weight basis.
  • buprenorphine is a schedule III controlled substance.
  • the combination formulation of buprenorphine/naloxone is generally prescribed to deter injection, since naloxone, an opioid antagonist, is believed to cause acute withdrawal if the formulation is crushed and injected.
  • naloxone an opioid antagonist
  • buprenorphine Before starting buprenorphine, individuals are generally advised to wait long enough after their last dose of opioid until they have some withdrawal symptoms to allow for the medication to bind the receptors, since if taken too soon, buprenorphine can displace other opioids bound to the receptors and precipitate an acute withdrawal. The dose of buprenorphine is then adjusted until symptoms improve, and individuals remain on a maintenance dose of 8- 16 mg. Because withdrawal is uncomfortable and a deterrent for many patients, many have begun to call for different means of treatment initiation. Some providers have begun to use the Bernese method, also known as microdosing, in which very small doses of buprenorphine are given while patients are still using street opioids, and without precipitating withdrawal, with medicine levels slowly titrated upward.
  • Bernese method also known as microdosing
  • buprenorphine Common adverse drug reactions associated with the use of buprenorphine, similar to those of other opioids, include nausea and vomiting, drowsiness, dizziness, headache, memory loss, cognitive and neural inhibition, perspiration, itchiness, dry mouth, shrinking of the pupils of the eyes (miosis), orthostatic hypotension, male ejaculatory difficulty, decreased libido, and urinary retention. Constipation and central nervous system (CNS) effects are seen less frequently than with morphine. Central sleep apnea has also been reported as a side effect of long-term buprenorphine use. Buprenorphine treatment carries the risk of causing psychological or physiological (physical) dependencies.
  • Topical oral compositions are designed to perform a function in oral cavity, but traditionally mostly referred to dental health protection as well as drug delivery. Due to anatomic composition and high vascularization oral cavity is a promising organ for the local and systemic application of drug substances.
  • Formulations can take solid forms (e.g., tablets, wafers, films, fibers, and patches), liquid forms (e.g., sprays and drops), and semi-solid forms (e.g., gels, ointments).
  • Antimicrobial formulations were the first topical oral compositions on the market. Due to the elution with saliva, the residence time of the mouth-dissolvable formulation in oral cavity is relatively short. Medical devices placed in the oral cavity that can reside for an extended period of time without disintegration and can be expectorated to play an important role in solving this problem. These include oral patches, films, wafers, periodontal chips and chewing gums.
  • Natural adsorbents and absorbents include charcoal, silica, diatomaceous earth, bentonite, kaolin, starch, sodium aluminosilicate, etc., have large outer and inner pore surface area available for adsorbing (binding) or absorbing (trapping) small molecular weight ingredients. These are used in water treatment, wine and water purification, chemicals refining, air cleaning etc. as well as cosmetic and pharmaceutical products, such as for topical delivery for pharmaceutical compositions, UV absorbents in sunscreen, deodorants, cation releasing and self-warming cosmetic products and many others.
  • the inventors are proposing the incorporation of absorbents and/or adsorbents to topical compositions that reside in oral cavity for certain amount of time allowing its detoxifying performance for improved oral health care and lower risk of dental diseases coming from extended toxin residence in mouth. They are also proposing the incorporation of saliva stimulants, including but not limited to natural essential oils, such as peppermint oil etc. containing volatile and/or pungent ingredients which can increase saliva production, to improve the scavenging of toxins accumulated in the salivary glands.
  • saliva stimulants including but not limited to natural essential oils, such as peppermint oil etc. containing volatile and/or pungent ingredients which can increase saliva production, to improve the scavenging of toxins accumulated in the salivary glands.
  • compositions that can be employed include those in and references 10-18 listed below, all of which are incorporated herein by reference.
  • the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a particular carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.”
  • adsorbents/absorbents could provide removal of unwanted substances in the oral cavity, either accumulated in salivary glands or excreted in saliva.
  • Oral cavity is a pool of enzymes, hormones, many low molecular weight organic substances as well as bacteria and metabolites. Some of them may have a negative effect on oral health, and even toxic.
  • Inventors are proposing application of topical oral compositions with safe and effective capacity to scavenge drugs and toxins from saliva.
  • this topical oral composition could comprises at least one “generally recognized as safe” adsorbent or absorbent for use in scavenging drugs/metabolites/toxins/bioagents from oral cavity. It could more specifically comprise “generally recognized as safe” adsorbents or absorbents in the range of from about 5 to 50 wt % of medical devices.
  • the composition can comprise at least one natural or synthetic saliva stimulant, wherein said topical oral composition is applied in oral cavity; for use in stimulating saliva production for aiding in scavenging of drugs/metabolites/toxins/bioagents accumulated in salivary glands, such as in the range of from about 0.1 to 5 wt % of topical oral composition.
  • Methods of use for scavenging drugs/metabolites/toxins/bioagents from saliva can generally include administering to the subject an topical oral composition comprising at least one adsorbent or absorbent and at least one saliva stimulant, such as wherein said topical oral composition is applied in oral cavity for up to 60 mins, depending on the adsorption/absorption behavior of the drug/metabolite/toxin/bioagent, without swallowing the said topical oral composition.
  • the topical oral composition is applied in oral cavity and chewed or masticated in the oral cavity for up to about 15 mins, and spit out/removed from the oral cavity.
  • Results showed that salivary gland concentrations of buprenorphine were > 100-fold higher than plasma concentrations 5 hrs after sublingual administration, whereas only 10-fold higher than plasma concentrations 5 hrs after i.v. dosing. In addition, others have found that buprenorphine increased the 5. mutans biofilm formation in an in vitro experiment.
  • topical oral compositions including, but not limited to oral patches, films and wafers, periodontal chips, chewing gums, possibly characterized as a Class I Medical device, firstly to stimulate the saliva production, and then to scavenge drugs/toxins from excreted saliva.
  • saliva production increases 3 times, even up to 7 times, upon chewing, primarily depending on the chewing gum taste (ref. 21 ). This could allow more drug (buprenorphine) to be excreted from the salivary gland, reducing the concentrations in salivary glands.
  • oral patches, films, wafers, and periodontal chips can serve as good delivery systems for saliva stimulants such as cholinergic agents.
  • the inventors have incorporated adsorbent/absorbent in topical oral composition matrix to scavenge toxic drugs (such as buprenorphine) from saliva to prevent the drug from being bioavailable again to the oral tissue.
  • Topical oral compositions could be further fortified by adding a natural-occurring antimicrobial ingredient with flavoring properties (such as clove oil) to aid in reduction of microbial load in oral cavity and increase the organoleptic acceptance and saliva production.
  • Topical oral compositions have been used as a vehicle for delivering drugs, but so far they have do not appear to have been employed in the safe removal of unwanted drugs or toxins from saliva (oral cavity), especially drugs that are accumulated in salivary gland that adversely affects oral health. Also, this approach can be used for removing other dietary and environmental toxins from saliva, delivering oral health benefit through cleaning oral cavity, and reducing the risk of tooth decay, cavities, infections, periodontal diseases, and loss of teeth.
  • Topical oral compositions such as, but not limited to oral patches, films, wafers, periodontal chips or chewing gums, would be an affordable and convenient composition for oral healthcare, an alternative method for oral diseases control.
  • a preliminary formulation of one topical oral composition such as chewing gum has been tested on lab scale, where the adsorbent/absorbent loading capacity of chewing gum was tested and found to be 30% of the chewing gum weight.
  • Preliminary experiments on adsorbents/absorbents buprenorphine scavenging capacity included four different materials (Fullers Earth, diatomaceous earth, zeolite and kaolin). The scavenging capacities of these adsorbents/absorbents were tested in vitro, exposing them for 4 hours to saliva containing physiologically relevant buprenorphine concentration (5 pM).
  • the best performing adsorbent/absorbent was diatomaceous earth, showing the scavenging capacity of 88.60%, and was chosen for testing in chewing gum matrix.
  • Preformulated chewing gum was loaded with 10% of diatomaceous earth, frozen, crushed and mixed with saliva with buprenorphine (5 pM) containing saliva (to obtain final adsorbent/absorbent concentration 10 and 30 mg/ml). After 15, 30 and 60 minutes of mixing, the content of buprenorphine in saliva was found to be lower by 36.70-62.21% (10 mg/ml adsorbent/absorbent) and 55.54-79.15% (30 mg/ml adsorbent/absorbent) compared to the control chewing gum composition.
  • the adsorbent was suspended in saline (pH 6) with 1% DMSO and 5% methanol (0.5 mg/ml) and poured into wells membrane insert, while the drug solution (70 pM for 5-FU and buprenorphine, and 2 pM for SN-38, in the same saline solvent) was poured onto the other side of the membrane, each in triplicate.
  • the wells were incubated at 37° C on a shaker (100 rpm).
  • the optimal contact time i.e. when the saturation of adsorbent with drug was achieved, was determined by testing the concentration of free unabsorbed drug (Ce) transferred across the membrane at different time points (0-120 min), as presented in FIGS. 1A-D.
  • buprenorphine has a net positive charge due to the protonated tertiary amine (FIG. 2A).
  • SN-38 is predominantly neutral, though there may be a very small fraction of molecules with a negative charge due to the hydrolyzed carboxylate form.
  • 5-FU is predominantly neutral with no net charge because the experimental pH is below its pKa value (7.8).
  • overall surface charge of bentonite at pH 6 is negative due to the silicate structure, which is not pH dependent and is permanent, while the edges contain hydroxyl groups (e.g., Al-OH or Si-OH) and are partially protonated giving a slight positive charge.
  • negatively charged bentonite has highest adsorption capacity for positively charged buprenorphine, compared to neutral 5-FU, or slightly negatively charged SN-38 showing quick desorption of poorly adsorbed molecule due to repulsion of the same (negative) charges. Therefore, buprenorphine was tested further for adsorption on diatomaceous earth (DE), a silica-based adsorbent originating from fossilized remains of diatoms, which is also negatively charged at pH 6 due to the deprotonation of silanol groups on its silica surface. However, the adsorption of buprenorphine on DE was slower and weaker, reaching saturation (42.51% adsorbed) by 90 min (FIG. ID).
  • DE diatomaceous earth
  • Adsorption of buprenorphine on bentonite was further evaluated by testing adsorption of different drug concentrations (50-130 pM) at saturation contact time (60 min), using migration assay described above. Based on the obtained equilibrium drug concentration and calculated adsorption capacity (qe), Langmuir isotherm was generated (FIG. 3), and this isotherm model was confirmed as the best fit to the experimental data, with R 2 of 0.98, indicating an excellent agreement between the model and adsorption behavior.
  • Example 3 Comparing buprenorphine scavenging capabilities of different adsorbents/absorbents
  • LC-MS/MS method for evaluating buprenorphine levels is used for testing the absorption/adsorption efficiency of three natural adsorbents/absorbents: Fuller’s earth (FE), Diatomaceous earth (DE), Zeolite (ZE), and Kaolin (KA) to remove buprenorphine from saliva.
  • Fuller’s earth (FE) Diatomaceous earth (DE), Zeolite (ZE), and Kaolin (KA) to remove buprenorphine from saliva.
  • FE Fuller’s earth
  • DE Diatomaceous earth
  • ZE Zeolite
  • KA Kaolin
  • the buprenorphine-saliva solution (5 pM) was tested against the suspension of adsorbent/absorbent (Fuller’s Earth (FE), Diatomaceous Earth (DE), Zeolite (ZE) and Kaolin (KA)) at the concentration of 25 mg/ml in PBS, each in triplicate, at 37° C on a shaker (200 rpm) and allowed to incubate for 4 hours.
  • adsorbent/absorbent Fe
  • Diatomaceous Earth DE
  • ZE Zeolite
  • KA Kaolin
  • Example 4 Addition of adsorbents/absorbents in Chewing Gum to improve buprenorphine scavenging capacity
  • adsorbents/absorbents DE stood out (84.17% buprenorphine scavenging capacity) (FIG. 4) and was chosen for further testing in composition matrix such as chewing gum.
  • preformulated chewing gum was loaded with DE (10% w/w initial gum weight). Blank extrudable chewing gum sheets were carefully heated to melt without burning. DE was mixed with melted blank chewing gum reaching 10% concentration and shaped into films (21 x 6 x 4 mm) when cooled. Gum pieces were flash frozen and crushed.
  • CTRL Control chewing gum composition
  • chewing gum formulation 1 was produced at laboratory scale (formulation 1) and then upscaled to pilot plant manufacturing (formulation 2).
  • Gum base is spread on the sugar-coated pans and placed in the oven at 185 - 200°F for a minimum of 2 - 3 hours. Melted gum is then mixed in a mixer with all other ingredients, except lubricant, until they are all incorporated. Mixture is dried on trays for a minimum of 24 hours (humidity below 40% is mandatory for this formula). Dried gum is ground with hammer mill and loaded into coating pan and mixed for 2-5 minutes with lubricant. Finally, the gum powder was screened and pressed using standard gum punches and pressed gum tablets were dispensed into foil pouch (FIG. 7).
  • Example 6 Additional Uses for the Compositions
  • the current use of the proprietary topical oral compositions will be used to test their efficacy in removing buprenorphine in saliva of patients diagnosed with opioid use disorder and receiving sublingual buprenorphine as treatment in a clinical study.
  • the inventors plan on conducting evaluation of real- world saliva levels of buprenorphine in 24 patients on sublingual buprenorphine and collect chewed gum samples from 6 patients using prototype formulation for analytical method development in next few months for future clinical study. They will continue working on the formulations, testing topical oral compositions capacity to scavenge other drug or food related toxins that reside in oral cavity, but also the influence of these compositions on bacterial strains in oral microbiome.
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne des compositions orales et leurs procédés d'utilisation. La composition orale comprend un ou plusieurs composés comprenant un absorbant ou un complexe absorbant, tel que du charbon de bois, de la silice, de la terre de diatomées, de la bentonite, du kaolin, de l'aluminosilicate de sodium, un absorbant/adsorbant synthétique, modifié en surface ou enrobé, permettant le piégeage de médicaments/métabolites/toxines/bioagents. La composition, telle qu'une gomme, sera prise par voie orale par un utilisateur et va transférer un médicament/un métabolite/une toxine/un agent biologique de la salive dudit utilisateur à la composition, puis sera retirée.
PCT/US2025/013523 2024-01-30 2025-01-29 Compositions orales topiques pour piéger des médicaments/toxines dans la salive et leurs procédés de fabrication et d'utilisation Pending WO2025165825A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463626748P 2024-01-30 2024-01-30
US63/626,748 2024-01-30

Publications (1)

Publication Number Publication Date
WO2025165825A1 true WO2025165825A1 (fr) 2025-08-07

Family

ID=96591205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/013523 Pending WO2025165825A1 (fr) 2024-01-30 2025-01-29 Compositions orales topiques pour piéger des médicaments/toxines dans la salive et leurs procédés de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2025165825A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870492A1 (fr) * 1997-04-11 1998-10-14 Carter-Wallace, Inc. Composition buccale contenant de l'hydroxyde d'aluminium, de l'oxyde de silicium et un agent tensioactif anionique
US20100135924A1 (en) * 2008-11-25 2010-06-03 George Endel Deckner Oral Care Compositions Comprising Fused Silica
US20170252276A1 (en) * 2014-07-21 2017-09-07 Colgate-Palmolive Company Abrasive Oral Care Composition
US20180325799A1 (en) * 2015-11-20 2018-11-15 Colgate-Palmolive Company Oral Care Composition Comprising Chitosan and Silica
WO2023148307A1 (fr) * 2022-02-04 2023-08-10 Sigrid Therapeutics Ab Composition de soin buccal comprenant des particules de silice poreuse

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870492A1 (fr) * 1997-04-11 1998-10-14 Carter-Wallace, Inc. Composition buccale contenant de l'hydroxyde d'aluminium, de l'oxyde de silicium et un agent tensioactif anionique
US20100135924A1 (en) * 2008-11-25 2010-06-03 George Endel Deckner Oral Care Compositions Comprising Fused Silica
US20170252276A1 (en) * 2014-07-21 2017-09-07 Colgate-Palmolive Company Abrasive Oral Care Composition
US20180325799A1 (en) * 2015-11-20 2018-11-15 Colgate-Palmolive Company Oral Care Composition Comprising Chitosan and Silica
WO2023148307A1 (fr) * 2022-02-04 2023-08-10 Sigrid Therapeutics Ab Composition de soin buccal comprenant des particules de silice poreuse

Similar Documents

Publication Publication Date Title
Caffarelli et al. Preseasonal local allergoid immunotherapy to grass pollen in children: a double‐blind, placebo‐controlled, randomized trial
RU2140266C1 (ru) Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
DK2224917T3 (en) Composition with nicotine and opipramol and its use
ES2609469T3 (es) Comprimidos resistentes al aplastamiento destinados a evitar el mal uso accidental y la desviación de uso ilícita
Uitti et al. Parkinsonism induced by solvent abuse
RU2770050C2 (ru) Способ лечения с применением традипитанта
JP2001523245A (ja) 肥満を治療するためのｎｋ−１受容体拮抗薬およびｓｓｒｉの使用
CN1413111A (zh) 右美沙芬和氧化酶抑制剂使患者摆脱麻醉药和抗抑郁药的用途
JP2013082735A (ja) ＰＴＥＮ阻害剤またはＭａｘｉ−Ｋチャンネルオープナー
CN102159077A (zh) 用于治疗神经性疼痛的方法
WO2010020585A1 (fr) Inhibiteurs de la recapture de la sérotonine destinés au traitement du syndrome de rett
KR20020081271A (ko) 물질 남용의 치료 방법
CN118267382A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
CN1794992A (zh) 治疗轻度认知缺损及预防或延缓阿尔茨海默病的方法
US20080311196A1 (en) All Day Rhinitic Condition Treatment Regimen
JP2008507577A (ja) 中枢神経系の障害を治療するための医薬
WO2025165825A1 (fr) Compositions orales topiques pour piéger des médicaments/toxines dans la salive et leurs procédés de fabrication et d'utilisation
EP2397143A1 (fr) Préparation de tétrodotoxine lyophilisée en poudre et son procédé de préparation
Hackendahl et al. The dangers of nicotine ingestion in dogs
ES2403193T3 (es) Composiciones que comprenden alprazolam para el tratamiento del insomnio primario y del insomnio asociado con estados de ansiedad y procedimientos para su preparación
RU2006137330A (ru) Пероральные матричные композиции, содержащие ликарбазепин
ITMI20010907A1 (it) Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
Bronkhorst et al. Pholcodine: treatment options for dry cough
M Farber et al. Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson’s disease
JP2020505448A (ja) ハンチントン病の治療のためのＰＰＡＲγアゴニスト

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25748814

Country of ref document: EP

Kind code of ref document: A1